Compound reference
GHK-Cu Dosage Guide 2026: The Research vs Reported Use
Short answer
What it is: GHK-Cu is a copper peptide, the tripeptide glycyl-l-histidyl-l-lysine bound to a copper ion. GHK, its parent tripeptide, circulates in blood and declines with age.
The trial doses: there is no human injectable trial dose. The human record is topical: a 0.4% cream ulcer trial (86 evaluable patients) and post-laser skin care (13 completers).
The headline number: GHK blood levels average 200 ng/mL at age 20 and fall to 80 ng/mL by 60.
The catch: the injectable milligram numbers online trace to forum protocols, not studies. The only injected doses in the cited record are in mice.
Why units still matter: research vials read in milligrams and syringes read in units. The two only agree once you know the vial's concentration.
The status: not FDA approved for injection or any other drug use, as of July 2026. Topical use is the studied lane, spanning cosmetics and wound care, and every trial figure here comes from the cited papers, DOIs at the bottom.
The calculator
How it works: put in a vial size, a water amount, a syringe type, and a dose in milligrams. It returns the concentration, the volume, and the syringe reading.
Units converter
Converts the numbers you type. It does not recommend a dose.
Arithmetic only. Check the result against your own vial, your own reconstitution, and your own syringe before you trust any unit count.
The Decadewise briefing
One compound, one paper, or one piece of math like this, every week. Free.
Education only. Unsubscribe anytime.
On this page
Community reports, not a protocol
What do people report running?
No log on this one: I have never run GHK-Cu, so there is no field log for it on this page. What follows is what community posts and vendor protocols describe, labeled as exactly that.
The vials: the 50mg vial is the common retail format in these posts. A 100mg vial shows up often too.
The amounts: forum and vendor protocols commonly list 1 to 2mg per day. One post planned 1.5mg daily for 30 days.
The lower end: dosage calculators aimed at the same audience default to 200 to 600mcg targets, well under the forum protocols.
The schedule: once daily or several times a week, in cycles of around 30 days.
The stack: pairing with BPC-157 comes up repeatedly in the same threads.
The topical lane: serums for skin and scalp get discussed too. That happens to be the lane the human trials actually studied.
The color tell: the solution turns faint blue-green when mixed. Posts treat it as normal, attributing the tint to the copper ion.
The frame: none of this is a trial, and none of it is my run. It is community convention, recorded so you can see where the numbers online actually come from.
Peer-reviewed research record
What does the research show?
The starting point: the human record is topical. Both randomized human trials in the cited record put GHK-Cu on skin, not in a syringe.
The ulcer trial: Bishop et al., Journal of Vascular Surgery, 1992, evaluated 86 patients with venous stasis ulcers on a 0.4% tripeptide copper complex cream against silver sulfadiazine or an inert placebo.
The result: the copper peptide cream did no better than placebo. Silver sulfadiazine reduced ulcer size against both.
The laser trial: Miller et al., Archives of Facial Plastic Surgery, 2006, randomized patients to skin care with or without GHK-Cu after CO2 laser resurfacing. Thirteen patients completed the study.
The split result: objective measures found no significant between-group difference, while patient satisfaction was significantly higher with GHK-Cu (P = .04).
The biology review: Pickart and Margolina, International Journal of Molecular Sciences, 2018, summarize the lab record: GHK stimulates blood vessel and nerve outgrowth and increases collagen, elastin, and glycosaminoglycan synthesis, with tissue repair shown across skin, lung, bone, liver, and stomach lining. That is the review's summary of mostly preclinical work, not human dosing data.
The plasma numbers: Dou et al., Aging Pathobiology and Therapeutics, 2020, put the natural decline in print: GHK averages 200 ng/mL at age 20 and 80 ng/mL by age 60.
The injectable record: the only injected doses in the cited record are in mice. Zhang et al., Frontiers in Molecular Biosciences, 2022, injected GHK-Cu intraperitoneally at 0.2, 2, and 20 micrograms per gram per day, on alternate days, in a cigarette-smoke emphysema model.
The 2026 verdict: a sports-medicine review of injectable peptides (Mayfield et al., American Journal of Sports Medicine, 2026) found GHK-Cu promising for wound healing and anti-inflammatory effects, with no clinical data supporting musculoskeletal use. Dosing, frequency, and duration remain unknown.
Don't merge these: reviews summarize mostly lab and animal work, and the human trials are small and topical. None of them tells you an injectable human dose, because there isn't one.
200
ng/mL, average plasma GHK at age 20
80
ng/mL, the average by age 60
86
patients in the topical ulcer trial, null vs placebo
13
patients in the post-laser topical trial
Dou et al. 2020; Bishop et al. 1992; Miller et al. 2006. Citations below.
Does the research dose match the internet dose?
The usual dodge: most pages hand you a schedule with no trial behind it. With GHK-Cu there is no injectable trial to hide behind at all, so we're doing neither.
What the research record is
What it is: topical and small. An ulcer trial with 86 evaluable patients that came out null against placebo, and a laser trial with 13 completers where only satisfaction moved. That is most of the randomized human record; the review also describes a 2016 randomized double-blind topical trial (Badenhorst et al.).
What it is not: a milligram number for injection. These trials were never built to answer that question.
What people run online
What the posts show: injected amounts of 1 to 2mg a day, 30-day cycles, 50mg vials. Every one of those numbers traces to forum convention and vendor calculators, community-reported behavior with no study behind it.
The honest gap: nobody on either side of this comparison has a tested human injectable dose, because no registered trial of one appears in the literature we pulled.
Picking your number out of those is not our job.
The real question: it is about your body, your risk tolerance, and a conversation with a doctor who knows your history. What we can give you is what the trials and the biology record published, plus the math behind a dose; the rest is yours to discuss with someone qualified.
How does the units math work?
The point: the arithmetic, once over, in general terms, with no dose attached to you.
Example one: say a 50mg vial gets reconstituted with 2mL of bacteriostatic water. That's 25mg per mL, or 25,000mcg per mL.
The syringe side: a U-100 insulin syringe holds 100 units per mL, each unit 1/100th of a mL, which at this concentration is 250mcg, or 0.25mg. From there: 1mg is 4 units, and 2mg is 8 units.
Change one thing: reconstitute the same 50mg vial with 3mL instead of 2mL. Concentration drops to about 16.7mg per mL.
What changes: each unit now equals about 0.167mg instead of 0.25mg. The same 1mg dose is now 6 units, not 4, and 2mg reads as 12 units.
The bigger vial: a 100mg vial with 2mL gives 50mg per mL. Each unit is 0.5mg, and 2mg reads as 4 units.
The forum trap: that "8 units" someone read on a forum could be 2mg at one concentration and 1.3mg at another.
| Vial plus water | Concentration | 1 unit equals | What the math gives |
|---|---|---|---|
| 50mg plus 2mL | 25mg per mL (25,000mcg per mL) | 0.25mg (250mcg) | 1mg is 4 units, 2mg is 8 units |
| 50mg plus 3mL | about 16.7mg per mL | about 0.167mg (167mcg) | 1mg is 6 units, 2mg is 12 units |
| 100mg plus 2mL | 50mg per mL | 0.5mg | 2mg is 4 units |
| Syringe | Units per mL | 1 unit equals |
|---|---|---|
| U-100 | 100 units per mL | 0.01mL |
| U-40 | 40 units per mL | 0.025mL |
Trap two: the syringe. Insulin syringes read in units at two scales, unrelated to concentration.
The two scales: U-100 measures 100 units per mL, one unit is 0.01mL. U-40 measures 40 units per mL, one unit is 0.025mL.
The 2.5x problem: grab a U-40 while working in U-100 numbers and every unit is 2.5 times the volume you think it is. Same vial, same concentration, same "8 units" on the barrel.
Confirm the syringe scale in your hand before any conversion.
Both halves: that is the entire units-versus-mg knot, both threads of it. The syringe reads honestly. It does not know your concentration or its scale; you do.
How many units is 2mg of GHK-Cu?
The short answer: it depends on the concentration. At 25mg per mL (a 50mg vial plus 2mL of water), 2mg reads as 8 units on a U-100 syringe. At about 16.7mg per mL (the same vial plus 3mL), 2mg reads as 12 units.
The rule: no milligram amount owns one universal units number. Concentration first, syringe type second, then the arithmetic, or the calculator above.
What's not known yet?
The status: GHK-Cu is not FDA approved for injection, or for any other drug use, as of July 2026. No NDA or BLA is on record for it, as of our 20 July 2026 check.
What that means: compounding pharmacies are not authorized to produce the injectable form, whose nomination was withdrawn from the FDA's Category 2 list, so the injectable vials sold online sit outside the approved-drug system entirely. Topical copper peptide spans cosmetics and wound-care trials, and it is the lane the human trials actually studied.
The real gaps:
- No human trial of injected GHK-Cu at any dose. The only injected doses in the cited record are in mice.
- No injectable human trial data. The 2026 sports-medicine review lists dosing, frequency, and duration as unknown.
- No verified data on the community protocols that dominate online discussion. None of it has been tested in a controlled trial.
- One registered trial is live: NCT07437586, a topical gel for acute skin wounds, recruiting as of July 2026. Topical again, not injection.
Anyone who asserts otherwise is guessing.
The biggest gap: in our read, one gap outweighs any dose number here. A research-grade vial gives you no independent verification of what is in it.
All taken on trust: identity, purity, sterility, and the genuine labeled concentration.
The quiet one: a mislabeled concentration breaks every units calc above. The math stands or falls on the mg number printed on the label.
The real worry: that is not a dosing question, a trust question, and it is what we would verify first, every time.
How this page is sourced
No secondary summaries: every research figure above comes straight from the cited papers, reviews named as reviews. Nothing was lifted from a secondary summary.
The six sources: below, with their DOIs and PubMed IDs. Pull them yourself, and test our numbers against theirs.
The standard: the sourcing and citation-verification standard for this site lives on the methodology page. Any number here that ever gets corrected lands there first.
Last reviewed: 19 July 2026.
-
1
Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. doi:10.3390/ijms19071987. PMID 29986520.
-
2
Dou Y, Lee A, Zhu L, Morton J, Ladiges W. The potential of GHK as an anti-aging peptide. Aging Pathobiol Ther. 2020;2(1):58-61. doi:10.31491/apt.2020.03.014. PMID 35083444.
-
3
Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-9. doi:10.1001/archfaci.8.4.252. PMID 16847171.
-
4
Bishop JB, Phillips LG, Mustoe TA, et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992;16(2):251-7. doi:10.1067/mva.1992.37086. PMID 1495150.
-
5
Zhang Q, Yan L, Lu J, Zhou X. Glycyl-L-histidyl-L-lysine-Cu(2+) attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway. Front Mol Biosci. 2022;9:925700. doi:10.3389/fmolb.2022.925700. PMID 35936787.
-
6
Mayfield CK, Bolia IK, Feingold CL, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. 2026;54(1):223-229. doi:10.1177/03635465251357593. PMID 41476424.
The disclaimer
Every page is reviewed by medical professionals before it ships, and written with longtime biohackers who were doing this before it was a trend. Reviewed still does not mean prescribed: nothing here is medical advice.
It is research, trial data, and reported use, with the numbers intact so you can check them. For decisions about your body, see a doctor who can look at your labs.
The weekly briefing
Get the next dosage guide.
New compound guides, new calculators, and the math behind the next panic post. One clear email a week.
Education only, never medical advice. Unsubscribe anytime.